Beyond fitness tracking: The use of consumer-grade wearable data from normal volunteers in cardiovascular and lipidomics research

Weng Khong Lim1,2*, Sonia Davila1,3*, Jing Xian Teo1, Chengxi Yang4, Chee Jian Pua4, Christopher Blöcker2, Jing Quan Lim5, Jianhong Ching3, Jonathan Jiunn Liang Yap6, Swee Yaw Tan6, Anders Sahlin6, Calvin Woon-Loong Chin6, Bin Tean Ten1,2,7,8,9, Steven G. Rozen1,2,10, Stuart Alexander Cook1,3,4,11,12*, Khung Keong Yeo6*, Patrick Tan1,2,9,13*

1 SingHealth Duke-NUS Institute of Precision Medicine, Singapore, 2 Cancer and Stem Biology Program, Duke-NUS Medical School, Singapore, 3 Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School, Singapore, 4 National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, 5 Lymphoma Genomic Translational Laboratory, Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 6 Department of Cardiology, National Heart Centre Singapore, Singapore, 7 Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, Singapore, 8 Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, 9 Cancer Science Institute of Singapore, National University of Singapore, Singapore, 10 Centre for Computational Biology, Duke-NUS Medical School, Singapore, 11 National Heart and Lung Institute, Imperial College London, United Kingdom, 12 MRC Clinical Sciences Centre, Imperial College London, United Kingdom, 13 Biomedical Research Council, Agency for Science, Technology and Research, Singapore

☯ These authors contributed equally to this work.

* wengkhong.lim@duke-nus.edu.sg (WKL); stuart.cook@duke-nus.edu.sg (SAC); yeo.khung.keong@nhcs.com.sg (KKY); gmstanp@duke-nus.edu.sg (PT)

Abstract

The use of consumer-grade wearables for purposes beyond fitness tracking has not been comprehensively explored. We generated and analyzed multidimensional data from 233 normal volunteers, integrating wearable data, lifestyle questionnaires, cardiac imaging, sphingolipid profiling, and multiple clinical-grade cardiovascular and metabolic disease markers. We show that subjects can be stratified into distinct clusters based on daily activity patterns and that these clusters are marked by distinct demographic and behavioral patterns. While resting heart rates (RHRs) performed better than step counts in being associated with cardiovascular and metabolic disease markers, step counts identified relationships between physical activity and cardiac remodeling, suggesting that wearable data may play a role in reducing overdiagnosis of cardiac hypertrophy or dilatation in active individuals. Wearable-derived activity levels can be used to identify known and novel activity-modulated sphingolipids that are in turn associated with insulin sensitivity. Our findings demonstrate the potential for wearables in biomedical research and personalized health.

Author summary

Little is known about how data from wearable sensors can be used apart from fitness tracking. We comprehensively studied 233 normal volunteers, integrating data from
wearable sensors with lifestyle questionnaires, cardiac imaging, sphingolipid profiling, and clinical measurements of various heart and metabolic disease markers. Apart from showing that wearable sensors can be used to identify groups of volunteers with distinct behavioral and demographic characteristics, we showed that resting heart rate (RHR) from wearables performed better than step counts in predicting heart and metabolic disease risk markers. Notably, we further demonstrated that wearable data could be used in 2 areas of biomedical research. In the field of cardiac imaging, we showed that activity data from wearables can be used to determine how the size of heart is influenced by physical activity. Wearable data could also identify active individuals that are more likely than others to have enlarged hearts and potentially be misdiagnosed with heart disease. In the field of lipidomics, we showed that wearable data can be used to identify species of sphingolipids that are affected by how active a person is. Some of these compounds are known to be associated with obesity, diabetes, and heart disease.

**Introduction**

Public adoption of consumer-grade wearable activity trackers (“wearables”) has been steadily increasing in recent years [1,2], and it is estimated that the global market for wearables will exceed $34 billion US$ by 2020 [3]. Basic activity trackers provide accelerometer-based activity data, whereas more sophisticated models are also capable of monitoring heart rate (HR).

Together, these indicators have the potential to provide deep insights into an individual’s cardiovascular health and fitness. For instance, resting heart rate (RHR) is an important indicator of cardiovascular health [4–6], whereas step counts can be used to infer patterns and levels of physical activity. Both metrics play roles in the modulation and prediction of risk of cardiovascular and metabolic disorders (CVMDs) [7].

Given the role played by physical activity in determining health outcomes, there has been great interest in the use of wearables in healthcare. Most research on wearables thus far has been focused on their utility in promoting increased physical activity in healthy and diseased populations [8]. Whereas most studies reported increased physical activity after wearable introduction [8], there is little evidence that this intervention results in clinically significant health outcomes. For instance, a year-long study conducted on corporate employees showed that although wearable introduction increased moderate to vigorous physical activity, it did not improve health outcomes [9]. Furthermore, only around 10% of participants were still using their wearable at study conclusion [9]. More recent studies have also started exploring how wearable data correlate with clinical and biological markers. In one study monitoring wearable data from 43 individuals over an average of 5 months, the authors showed that disease states and physiological differences between individuals (e.g., insulin sensitivity and inflammation) could be discerned from the data [10]. Another study seeking to determine how comprehensive personal data collected from 108 individuals correlated with physiology and disease did not identify any significant correlations with wearable data [11]. There are also studies exploring the use of time series HR data from wearables in the detection of conditions associated with cardiovascular disease such as atrial fibrillation (AF), sleep apnea (SA), and hypertension [12–14]. For example, deep neural networks (DNNs) trained on HR and step count data obtained from the Apple Watch (Apple, www.apple.com) were able to detect AF, SA, and hypertension at accuracies of 97%, 90%, and 82%, respectively [13,14].

Despite these advances, the lack of comprehensive datasets that integrate wearable metrics with other data types means that the utility of consumer-grade wearables to basic,
Use of wearable data in cardiovascular and lipidomics research

translational, and clinical research, as well as personalized health, remains largely uncharacterized. In this study, our goal was to investigate the utility of consumer-grade wearables in cardiovascular and lipidomics research. To that end, we generated multidimensional data from 233 normal individuals recruited for a longitudinal study (SingHEART/BioBank; National Heart Centre Singapore [NHCS], https://www.nhcs.com.sg). Subjects were tracked using a consumer-grade wearable activity and HR tracker (Fitbit Charge HR; Fitbit, www.fitbit.com), in addition to comprehensive profiling through lifestyle questionnaires, clinical measurements (e.g., weight, height, waist circumference [WC], blood pressure, etc.), lipid panel values, blood glucose test, cardiac magnetic resonance imaging (CMR), and lipidomic profiling. We then performed integrative analysis of the dataset in order to answer three specific questions. First, can wearable metrics obtained from study subjects provide insights into their behavioral and demographic characteristics? Second, how well do wearable metrics (both step- and HR-based) correlate with CVMD risk markers such that they are useful in the areas of clinical and/or translational research and personalized health monitoring? Finally, can wearable-derived metrics be used to support basic research, particularly in the analysis of cardiac imaging and lipidomic profiling data?

Results

Characteristics of the volunteer cohort

The cohort of 233 volunteers was tracked for a median duration of 4 days (range 2–6 days) per subject. Summary statistics of this cohort are shown in Table 1 (full details in S1 Data). The cohort had a median age of 48 years (range 21–69 years) and displayed a female bias (137/233, 58.8%). The average daily steps ("DailySteps") median was 10,395 steps per day, which is consistent with a recent study that compared Fitbit Flex (Fitbit, www.fitbit.com) and ActiGraph (http://actigraphcorp.com/) measurements in 104 Singapore-resident individuals (median steps/day = 10,193) [15]. There was no significant difference in DailySteps between male and female subjects (Student t test, \( p = 0.604 \)). In terms of wearable-derived HR metrics, median average day and night HR were 75 bpm and 61 bpm, respectively, with a median RHR of 69 bpm. We compared wearable-derived RHR (denoted henceforth as "RestingHR") with in-clinic measurements obtained from two sources, namely RHR measured by an automatic blood pressure monitor (ABPM_HR) and during an electrocardiogram test (ECG_HR). We found that RestingHR correlated better with ECG_HR, which is a generally accepted benchmark (\( r_s = 0.541; p = 2.434 \times 10^{-18} \)), as compared with ABPM_HR (\( r = 0.541; p = 2.506 \times 10^{-33} \)), \( r_s \) showed that RestingHR and ABPM_HR were on average higher than ECG_HR (mean difference = 5 bpm and 9 bpm, respectively), with RestingHR having better agreement with ECG_HR (95% limits of agreement = \(-9 \) bpm, 20 bpm) compared with ABPM_HR (95% limits of agreement = \(-12 \) bpm, 30 bpm). This suggests that RestingHR is relatively accurate and comparable to clinical measurements. Active [10,17] volunteers (DailySteps > 8,000) had lower RestingHR compared with their sedentary counterparts, even after accounting for age, gender, and body mass index (BMI; \( \beta = -3.185; p = 0.001 \)). This observation was also significant when using either continuous step counts (0.252 bpm less per 1,000 additional steps; \( p = 0.021 \)) or when using self-reported total activity (1.723 bpm less per additional unit; \( p = 4.080 \times 10^{-6} \)).

Wearable metrics provide insights on behavioral and demographic stratification of volunteers

Because volunteers comprised males and females of varying age groups ranging from 21 to 69 years, we sought to determine whether there were clusters of volunteers defined by common
activity patterns. We obtained per-volunteer daily activity profiles by averaging step counts from multiple days by time of day. These daily profiles were then clustered using unsupervised k-means clustering (k = 3), with Pearson correlation as a distance measure (Fig 1A). The 3 resulting clusters, of sizes 62, 63, and 108, respectively, showed distinct differences in terms of peak activity periods (Fig 1A). The first (AM cluster) showed peak activity in the morning, whereas the second (PM cluster) showed peak activity in the evening. A third cluster (MidDay cluster) showed a more even distribution of activity, peaking in midday (Fig 1B).

To further characterize these activity clusters, we compared the distribution of subject age and gender among the 3 clusters. There was no significant difference in gender composition among the clusters. For age, there was a slight trend towards older volunteers in the AM cluster, and younger volunteers in the PM cluster (Fig 1D). For gender, there was a slight trend towards more female volunteers in the AM cluster and more male volunteers in the PM cluster (Fig 1D).

Table 1. Summary statistics of volunteers, grouped by gender.

| Characteristic       | Female (n = 137; 58.8%) | Male (n = 96; 41.2%) | Test   |
|----------------------|------------------------|----------------------|--------|
| Age, years           | 47.49 (11.44)          | 44.36 (12.63)        | 0.051  |
| Ethnicity            |                        |                      | 0.257  |
| Chinese              | 127 (92.7)             | 85 (88.5)            |        |
| Malay                | 4 (2.9)                | 3 (3.1)              |        |
| Indian               | 2 (1.5)                | 6 (6.2)              |        |
| Others               | 4 (2.9)                | 2 (2.1)              |        |
| BMI, kg/m²           | 22.68 (3.89)           | 24.65 (3.98)         | <0.001 |
| WC, cm               | 78.33 (10.14)          | 88.54 (10.88)        | <0.001 |
| SBP, mmHg            | 122.80 (17.36)         | 133.81 (15.64)       | <0.001 |
| DBP, mmHg            | 72.88 (12.50)          | 83.12 (11.51)        | <0.001 |
| RestingHR, (Fitbit, bpm) | 70.37 (6.85)         | 68.72 (6.80)         | 0.07   |
| ECG_HR, bpm          | 64.87 (9.58)           | 63.45 (11.13)        | 0.304  |
| Total Cholesterol, mmol/l | 5.33 (1.02)          | 5.26 (0.85)          | 0.581  |
| LDL, mmol/l          | 3.28 (0.84)            | 3.37 (0.92)          | 0.471  |
| HDL, mmol/l          | 1.60 (0.34)            | 1.33 (0.32)          | <0.001 |
| TGs, mmol/l          | 0.98 (0.49)            | 1.34 (0.88)          | <0.001 |
| Glucose, mmol/L      | 5.24 (0.41)            | 5.44 (0.64)          | 0.005  |
| DailySteps, (Fitbit, x1000) | 10.74 (4.13)      | 11.00 (3.66)         | 0.612  |
| Fitbit ActivityClass | 0.799                  |                      |        |
| Cat I                | 14 (10.2)              | 10 (10.4)            |        |
| Cat II               | 57 (41.6)              | 36 (37.5)            |        |
| Cat III              | 54 (39.4)              | 38 (39.6)            |        |
| Cat IV               | 12 (8.8)               | 12 (12.5)            |        |
| GPPAQ Score          | 1.25 (1.12)            | 1.84 (1.15)          | <0.001 |
| LVM, g               | 64.13 (14.49)          | 93.16 (21.29)        | <0.001 |
| LVEDV, ml            | 107.79 (16.90)         | 137.36 (25.37)       | <0.001 |
| RVEDV, ml            | 106.21 (19.00)         | 141.74 (22.65)       | <0.001 |
| AoF, ml              | 65.62 (9.37)           | 78.39 (12.72)        | <0.001 |

Test p-values for between-gender comparisons are shown: For continuous variables, Student t test was used, whereas categorical values were evaluated using the chi-squared test. The full dataset is available in S1 Data, and this table was generated by code in S2 Data.

Abbreviations: AoF, aortic forward flow; BMI, body mass index; Cat, category; DailySteps, average daily steps; DBP, diastolic blood pressure; ECG_HR, electrocardiogram heart rate; GPPAQ, General Practice Physical Activity Questionnaire; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVEDV, left ventricular end-diastolic volume; LVM, left ventricular mass; RestingHR, wearable-derived RHR; RHR, resting heart rate; RVEDV, right ventricular end-diastolic volume; SBP, systolic blood pressure; TG, triglyceride; WC, waist circumference.

https://doi.org/10.1371/journal.pbio.2004285.t001
among the clusters, and the average ages of subjects in the clusters were 50 (AM), 43 (PM), and 46 (MidDay) years (Fig 1C). Mean age among the clusters was significantly different (one-way ANOVA, $p = 0.002$), with the AM cluster having older subjects compared with the PM cluster (Tukey’s test, $p = 0.002$).

We next considered sleep tracking data and characterized sleep and wake times across the clusters. On average, sleep tracking data revealed that our volunteers spent 6 hours and 57 minutes asleep each day, which is consistent with other studies [18]. Average sleep times for the AM, PM, and MidDay clusters were at hours 23:18, 00:07, and 23:40, respectively, whereas average wake times were at hours 06:39, 08:10, and 07:43, respectively (Fig 1D). There was a significant difference in sleep times among the clusters (one-way ANOVA, $p = 1.3 \times 10^{-6}$), with the AM cluster going to bed earlier than the PM cluster (Tukey’s test, $p = 7.18 \times 10^{-5}$) and the PM cluster having a later sleep time compared with the MidDay cluster (Tukey’s test, $p = 0.019$). Similarly, wake times were different between clusters (one-way ANOVA, $p = 8.98 \times 10^{-6}$), with the AM cluster waking up earlier compared with both the PM cluster

Fig 1. Stratification of volunteers based on wearable-derived activity metrics. (A) Heatmap showing activity profiles of study subjects over a 24-hour period, grouped by cluster (red = AM, green = PM, blue = MidDay). (B) Average activity profiles of the AM, PM, and MidDay clusters, respectively. (C) Boxplots showing the age distribution of each cluster. (D) Distribution of sleep and wake times for each cluster. The code to generate this figure can be found in S2 Data. Asterisks denote significance of Tukey’s range test between cluster pairs. * = $p < 0.05$; ** = $p < 0.01$; *** = $p < 0.001$.

https://doi.org/10.1371/journal.pbio.2004285.g001
Tukey’s test $p = 1.47 \times 10^{-5}$) and the MidDay cluster (Tukey’s test $p = 3.80 \times 10^{-4}$). The significant disparities in age and sleep timing between the AM and the PM clusters reflect lifestyle differences that could, in part, be explained by previous reports of an advance in circadian timing with aging [19].

**Wearable metrics are associated with clinical risk markers**

One key aim of this study is to characterize the relationship between wearable metrics and clinical parameters of relevance to CVMD risk. To that end, volunteers had various clinical parameters measured in the clinic upon recruitment, including BMI, WC, systolic blood pressure (SBP), diastolic blood pressure (DBP), as well as fasting levels of total cholesterol (TotalChol), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides (TGs) and fasting blood glucose (FBG). Wearable metrics of interest that were evaluated against these clinical parameters comprised DailySteps and RestingHR. For comparison, we also evaluated clinically measured RHR values (ECG_HR), as well as questionnaire-derived activity scores (General Practice Physical Activity Questionnaire [GPPAQ]).

After categorizing our volunteers according to commonly used clinical thresholds (see Materials and methods), we used logistic regression to determine the extent to which wearable metrics are associated with clinical risk markers. For models using DailySteps, adjustments were made for age, BMI, and gender as well as interaction between gender and steps in order to account for known gender-specific differences in metabolism and response to chronic exercise [20,21]. For models using RestingHR, age and gender were included as independent covariates.

We found that RestingHR is a better predictor compared with DailySteps (Fig 2, S1 Table). Whereas RestingHR was significantly associated with 7/9 clinical markers, DailySteps was only significantly associated with lower odds of having high BMI, WC, and TG values in more active males. For instance, male subjects benefitted more from taking more steps per day in terms of reduced risk of obesity (high BMI) compared with their female counterparts (odds ratio [OR] 0.710; $p_{\text{interaction}} = 0.002$; Fig 2). In contrast, questionnaire-based activity score (GPPAQ) was not significantly associated with any clinical parameters (S1 Table).

Next, we compared RestingHR to gold standard clinical RHR (ECG_HR). For clinical markers that were significantly associated with either measure, RestingHR achieved more significant $p$-values than ECG_HR in all clinical markers except for SBP and DBP, probably due to ECG_HR, SBP, and DBP all being measured during the same clinic visit (S1 Table). This suggests that RestingHR is comparable to gold standard ECG_HR in associating with CVMD risk makers.

**Exercise-induced cardiac remodeling can be identified through wearable-inferred physical activity levels**

A portion of the volunteers underwent CMR imaging. We therefore sought to determine whether wearable-derived metrics could be used in the analysis of cardiac imaging data. In particular, we were interested in whether wearable-derived physical activity was correlated with cardiac remodeling because recent work done using activity questionnaires had indicated that exercise-induced cardiac remodeling (EICR; also known as athlete’s heart) is not exclusive to athletes but can also occur in moderately active individuals [22]. We considered cardiac parameters associated with EICR, namely left ventricular mass (LVM; $n = 202$), left ventricular end-diastolic volume (LVEDV; $n = 216$), right ventricular end-diastolic volume (RVEDV; $n = 126$), and aortic forward flow (AoF; $n = 202$). The relationship between wearable-derived activity and cardiac parameters was assessed using multiple linear regression adjusting for age, gender, and SBP (covariates and indexing methods used are described in the Materials and methods section). Because cardiac remodeling is more pronounced at the more extreme end
of physical activity levels, we also considered DailySteps binned with cutoffs at the 10th, 50th, and 90th percentiles to produce 4 categories (Categories I–IV). We found that both continuous and categorical step counts were significant predictors for all 4 cardiac parameters (Fig 3, S2 Table). After adjusting for covariates, DailySteps (x1,000) was a significant predictor for LVM ($\beta = 0.353; p = 0.012$), LVEDV ($\beta = 0.386; p = 0.010$), RVEDV ($\beta = 0.617; p = 0.003$), and AoF ($\beta = 0.466; p = 0.003$). We next determined the risk of having abnormally high LVM (indexed to body surface area [BSA]) among our very active volunteers because this is the characteristic most associated with EICR. Those in the upper quartile of DailySteps were more likely to exceed upper population-matched reference limits [23] compared with other volunteers (OR 3.239; CI 1.133–9.276; $p = 0.026$). We also considered RestingHR as a predictor for these cardiac parameters and found it only significant for LVEDV, RVEDV, and AoF but not for LVM (S2 Table). In summary, the integration of wearable activity metrics and cardiac imaging data can reveal relationships between exercise and cardiac remodeling in normal individuals.

### Wearable metrics identify sphingolipid species associated with physical activity and insulin resistance

A subset of volunteers ($n = 112$) underwent serum sphingolipid profiling to determine the abundance of various species of circulating sphingolipids, namely ceramides, sphingomyelins, lactosylceramides, and glucosylceramides. Because circulating sphingolipids, especially...
ceramides, have been shown to be correlated with cardiorespiratory fitness and exercise [24–26], we sought to determine whether wearable-derived physical activity can contribute to the discovery of relationships between activity and sphingolipid abundance.

Using multiple regression to account for age, gender, and BMI, we identified 12 sphingolipids (Table 2, Fig 4) that were significantly associated with DailySteps ($p < 0.05$), 8 of which had a false discovery rate (FDR)–adjusted $p$-value less than 0.1. All significant sphingolipids were negatively associated with DailySteps. Of these, the specific sphingolipids most significantly ($p < 0.01$; $q < 0.1$) associated with DailySteps included Cer(d18:1/18:0), Cer(d18:1/
20:0), and Cer(d18:1/24:1(15Z)), ceramides previously reported to be negatively correlated with cardiorespiratory fitness as measured by peak oxygen consumption in volunteers [25].

We also identified associations among precursor dihydroceramides Cer(d18:0/20:0) and Cer(d18:1/24:1(15Z)), which have been linked to obesity [24,27]. Together, this suggests that wearable-derived physical activity is capable of identifying relationships between lifestyle and serum ceramide abundance. Apart from ceramides, we identified novel associations among Table 2. List of sphingolipids significantly associated with DailySteps.

| Sphingolipid                | DailySteps (x1,000) p-value | β | FBG p-value | β |
|-----------------------------|-----------------------------|---|-------------|---|
| Cer(d18:1/20:0)             | 0.002                       | −0.073 | 0.031 | 0.112 |
| Cer(d18:0/20:0)             | 0.004                       | −0.066 | 0.434 | 0.044 |
| Cer(d18:1/24:1(15Z))        | 0.004                       | −0.067 | 0.391 | 0.045 |
| Cer(d18:1/18:0)             | 0.005                       | −0.071 | 0.024 | 0.112 |
| Cer(d18:0/24:1(15Z))        | 0.009                       | −0.062 | 0.502 | 0.035 |
| Cer(d18:1/16:0)             | 0.013                       | −0.061 | 0.575 | 0.028 |
| Cer(d18:1/22:0)             | 0.014                       | −0.060 | 0.055 | 0.095 |
| SM(36:0)                    | 0.015                       | −0.056 | 0.024 | 0.123 |
| Cer(d18:1/24:0)             | 0.023                       | −0.053 | 0.188 | 0.067 |
| SM(36:1)                    | 0.027                       | −0.051 | 0.045 | 0.109 |
| GlcCer(d18:1/16:0)          | 0.043                       | −0.043 | 0.066 | −0.113 |
| SM(36:2)                    | 0.048                       | −0.045 | 0.021 | 0.125 |

Associations with DailySteps are adjusted for age, gender, and BMI. Sphingolipids significant after FDR (false discovery rate) correction (q < 0.1) are highlighted in bold, whereas those that are also significantly associated with FBG levels are marked with an asterisk (*). The code to generate this table can be found in S2 Data.

Abbreviations: BMI, body mass index; Cer, ceramide; DailySteps, average daily steps; FBG, fasting blood glucose; FDR, false discovery rate; GlcCer, glucosylceramide; SM, sphingomyelin.

https://doi.org/10.1371/journal.pbio.2004285.t002

Fig 4. Wearable-derived activity and sphingolipid abundance. Heatmap showing the abundance of sphingolipids that are significantly associated with DailySteps. Columns represent volunteers ordered by increasing DailySteps. For comparison, values of FBG and DailySteps are shown. All values are z-score normalized by row. The code to generate this figure can be found in S2 Data. Cer, ceramide; DailySteps, average daily steps; FBG, fasting blood glucose; GlcCer, glucosylceramide; SM, sphingomyelin.

https://doi.org/10.1371/journal.pbio.2004285.g004
several sphingomyelins (SM(36:0), SM(36:1), SM(36:2)) and a glucosylceramide (GlCer (d18:1/16:0)), all of which were lower in more active subjects. We then compared the abundance of these activity-associated sphingolipids with FBG levels and found that 5 of them were also positively associated with FBG ($p < 0.05$). These included ceramides (Cer(d18:1/18:0), Cer(d18:1/20:0)) and sphingomyelins (SM(36:0), SM(36:1), SM(36:2)) (Table 2). In line with our findings, levels of ceramides (Cer(d18:1/18:0), Cer(d18:1/20:0))—as well as sphingomyelin SM(36:1) in plasma and skeletal muscle—have been reported to be correlated with insulin resistance [26,28–31]. This analysis was also repeated using RestingHR as a metric; however, no significant associations were identified after accounting for multiple testing. These results suggest that activity metrics from consumer-grade wearables are sufficiently accurate to yield biologically relevant insights from lipidomics datasets.

**Discussion**

The data we presented above show that even short-duration wearable studies can provide value to biomedical science, particularly in cardiovascular and lipidomics research. Our analysis of time series activity data shows that wearable metrics can stratify a cohort into behavioral clusters with distinct characteristics. This approach can assist researchers seeking to correlate lifestyle physical activity with health outcomes.

Our characterization of the relationships between wearable metrics and CVMD markers can also be used to inform future wearable studies. Specifically, we found that RHR metrics are superior to step-based ones in terms of association with CVMD markers. However, this was not the case for the cardiac imaging and lipidomics data. This is likely attributable to RHR being a strong determinant of CVMD risk [5]. Conversely, unlike RHR, the relationship between activity and CVMD risk is less straightforward because it is subject to many confounders not captured in this study, of which diet is likely to be a key factor. Such relationships may only become apparent with larger sample sizes and diverse cohorts [32].

Despite rising adoption of wearables for personal activity and fitness tracking, the translation of wearable metrics into actionable health insights remains a challenge. Our results show that, with respect to CVMD risk, RHR values from wearables are equivalent to—if not better than—clinical RHR measurements. With wearables, users can continuously monitor RHR, enabling early detection of deviations in RHR that herald changes to CVMD risk markers such as weight gain and hypertension [33]. This may improve upon the status quo, whereby individuals are typically only made aware of changes to health status and disease risk during infrequent health checkups. Notably, the correlation between wearable metrics and fasting glucose suggests that wearables may provide an early indication of increased diabetes risk, which is vital given that a large number of Singaporeans have undiagnosed diabetes [34]. From a healthcare research perspective, continuous RHR tracking may become essential in long-term studies tracking lifestyle and health parameters because it could provide a high-resolution view of how changes in lifestyle impact cardiovascular health. Such insights, potentially emergent from large-scale efforts such as Project Baseline (http://www.projectbaseline.com), will also help formulate ways to present wearable data to users in ways that promote compliance with healthy lifestyle behaviors and facilitate early detection of disease states.

Our findings on the utility of wearables in analyzing CMR data and identifying individuals at risk of having abnormally high LVM have clinical and research implications. EICR is a benign adaptation to increased cardiovascular load resulting from exercise [35], although there are conflicting reports of malignant adaptation to excessive exercise [36,37]. Initially thought to be exclusive to competitive athletes, a recent population study found that 14% of individuals in the most active category met imaging criteria for left ventricular hypertrophy.
Overlapping features between EICR and hypertrophic cardiomyopathy pose a risk of overdiagnosis by clinicians faced with abnormal findings in nonathletic patients, particularly at a time when regular exercise is heavily promoted to the public [35,38]. Apart from increased awareness of this phenomenon by clinicians, wearable metrics can play a role in differentiating between pathologic and physiological remodeling. CMR is the preferred imaging modality for population-scale health studies (e.g., UK Biobank \( n = 100,000 \) [39], German National Cohort \( n = 30,000 \) [40], Canadian Partnership for Tomorrow \( n = 10,000 \) [41]) because it avoids exposure to ionizing radiation or contrast agents [39]. Our findings hint at a wider role for wearables in population studies aiming to dissect the relationship between lifestyle and cardiac function. The rising number of normal individuals undergoing CMR as part of population-scale studies implies that a non-negligible fraction will be flagged with abnormal CMR findings. Where follow-up of incidental findings is consented and authorized, wearables could thus play a role in reducing the risk of overdiagnosis.

Ceramides are sphingolipids involved in cellular stress response and are linked to pathological conditions such as insulin resistance, obesity, and cardiovascular disease [42]. Furthermore, higher levels of cardiorespiratory fitness are associated with lower plasma ceramide abundance, suggesting that physical activity may play a beneficial role in regulating levels of these molecules. Using wearable-derived activity data, we identified specific sphingolipids associated not only with activity but also with insulin resistance. Among the top activity-associated sphingolipids, 3 ceramides—Cer(d18:1/16:0), Cer(d18:1/18:0), and Cer(d18:1/24:1 (15Z))—have been previously shown to predict risk of major adverse events due to cardiovascular disease [43,44] and have been included in clinical laboratory tests [45], showing that our approach can identify lifestyle-modifiable sphingolipids linked to health outcomes. Whereas previous studies investigating relationships between cardiorespiratory fitness and circulating ceramides have been interventional [25,46] (i.e., using exercise training programs or graded treadmill test), we found that analysis of baseline wearable-derived activity levels can also provide insights into such relationships. Future studies, including population cohorts, could be conducted using commodity wearable devices, ultimately enabling more data to be collected while reducing study complexity.

One limitation of this study is the relatively short duration of the tracking periods, thus compromising power to detect associations between activity and CVMD markers. Our cardiac imaging and lipidomics analyses suggest that longer tracking periods, particularly feasible when volunteers share data from their personal devices, will prove to be even more useful. Additionally, volunteers recruited into this cohort may be enriched for those with a higher level of regard for their health and well-being. There was limited examination of time series (as opposed to summary)–wearable data. Activity cluster membership (with the AM cluster as reference) was tested as a predictor for all the association analyses in this study; however, apart from LVEDV \( (p_{PM\_cluster} = 0.071; p_{MidDay\_cluster} = 0.014) \) and AoF \( (p_{PM\_cluster} = 0.467; p_{MidDay\_cluster} = 0.025) \) in the cardiac imaging data, there were no other significant associations. Further studies on the utility of features derived from the time series data (e.g., HR variability, HR recovery, activity intensity) are therefore warranted.

In summary, we have characterized in a sizeable cohort the relationship between wearable metrics and a wide range of volunteer phenotypes including lifestyle patterns, demographics, CVMD clinical markers, cardiac imaging, and serum sphingolipid profiles. Our findings show that apart from fitness tracking, consumer-grade wearables can play a role in both basic and clinical research. Such wearables could also provide a low-cost means for early detection of changes in an individual’s personal CVMD risk profile, potentially resulting in more timely detection and intervention of CVMDs.
Materials and methods

Study volunteers and ethics statement

The SingHEART/Biobank study was established at the NHCS to characterize normal reference values for various cardiovascular and metabolic disease-related markers in Singaporeans. Normal volunteers were enrolled into this study using a protocol and written informed consent form approved by the SingHealth Centralized Institutional Review Board (ref: 2015/2601). The volunteers underwent comprehensive profiling in the following areas: (1) activity tracking using the Fitbit Charge HR wearable sensor, (2) physical activity and lifestyle questionnaire, (3) CMR imaging, (4) serum sphingolipid profiling, (5) fasting lipid and glucose panel, and (6) assessment of clinical parameters (e.g., HR, blood pressure, BMI). A total of 233 volunteers were included in this study after evaluation for completeness of activity tracking data (details below) and removal of subjects with extreme outlier activity metrics (potentially due to improper wearable usage). Inclusion criteria were as follows:

1. Aged between 21 and 69 years.
2. No personal medical history of myocardial infarction (MI), coronary artery disease (CAD), peripheral arterial disease (PAD), stroke, cancer, autoimmune/genetic disease, endocrine disease, diabetes mellitus, psychiatric illness, asthma, or chronic lung disease and chronic infective disease.
3. No family medical history of cardiomyopathies.

Activity tracking

Volunteers were issued a Fitbit Charge HR wearable activity tracker to be worn over a course of 5 days (e.g., typically Monday–Friday). However, because the first and last days of the study tended to be partial days, the average yield for each study was 3 days of complete tracking (defined as ≥20 hours with steps and HR data). Data for each subject were downloaded from the Fitbit website using the “fitbitScraper” package (https://github.com/corynissen/fitbitScraper; NB: This method of data access is now deprecated; the same data can be obtained through the Fitbit API at https://dev.fitbit.com/reference/web-api/quickstart). Step counts were available at 2 levels: intraday step counts in 15-minute intervals and daily totals. Intraday HR data were available at 5-minute intervals, along with confidence levels. Intraday sleep tracking data containing details of each sleep session were also retrieved.

To determine data completeness, we used HR confidence values as an indicator that the subject is wearing the device. HR data points with confidence value of “−1” were considered to be invalid (i.e., device was not worn or was incorrectly worn). First, the HR values table was merged with the steps table by their time points. We then counted the number of hours per day that contained HR data with a valid confidence value. Days with ≥20 valid hours were considered to be complete. Furthermore, days with no intraday step data were excluded. Such events typically arose due to delayed syncing of the device resulting in older data being overwritten.

To determine RestingHR, we calculated the average HR value for time points that met the following criteria: (1) had ≤100 steps take place within the 15-minute interval and (2) had a valid HR value. Day HR was similarly obtained but by restricting to time points between 2 PM and 4 PM, whereas night HR sampled time points between 2 AM and 4 AM.

For DailySteps estimation, we obtained the average sum of steps that took place in data-complete days. We also derived estimated daily steps using an alternative method. Briefly, we obtained step-count data points across data-complete days that were matched with valid HR
values. We then calculated estimated daily steps by multiplying the average of these step-count values by 96 (i.e., the number of 15-minute intervals per day). Daily step values derived through both methods were highly correlated ($r_s = 0.955; p < 2.2 \times 10^{-16}$). We thus used Daily-Steps as a measure of wearable-derived physical activity for the rest of this study.

Sleep tracking data was processed as follows: the amount of sleep for each day was determined by summing the duration of all sleep sessions for that day. An average sleep duration was then obtained from the data-complete days. Sleep hour was determined by calculating the average start time of sleep sessions occurring between 7 PM and 4 AM. Wake hour was determined by averaging the end time of sleep sessions. Only subjects with average sleep duration, sleep hour, and wake hour that were within 2 standard deviations (SDs) from mean values were included for statistical analysis in the study (216/233 subjects).

**Clustering of daily activity profiles**

For each volunteer, we obtained a 24-hour daily activity profile in the following manner. First, step-counts were smoothed across sliding windows of 5 time points. Then, step-counts from multiple data-complete days were collapsed into a single average profile by averaging step-counts from the same daily time point. Time points with no valid step counts were filled with zeros, and the daily profile was again smoothed in 5–time point sliding windows. Volunteers were clustered using unsupervised k-means clustering ($k = 3$) with Pearson correlation as a distance measure.

**Physical activity questionnaire**

As part of the study, volunteers answered several questionnaires to ascertain their lifestyle. Physical activity was primarily assessed using the GPPAQ (https://www.gov.uk/government/publications/general-practice-physical-activity-questionnaire-gppaq). Briefly, subjects provide information on amount spent in the last week on the following activities: (1) physical exercise, (2) cycling, (3) walking, (4) housework, and (5) gardening and/or do-it-yourself activity. Additionally, volunteers were asked of the amount of physical activity involved in their occupations, as well as their walking pace. A physical activity index (PAI) was generated based on the amount of physical exercise and/or cycling as well as their occupational activity level. The PAI has four activity levels: Inactive, Moderately Inactive, Moderately Active, and Active. These are treated as numerical scores in this study. In this study, amount of cycling was not factored into PAI derivation in order to facilitate a more direct comparison with wearable-derived activity.

**Clinical parameters**

The following measurements were performed on the day of volunteer recruitment. First, weight and height were measured using a SECA703 weighing scale (Seca), whereas SBP and DBP were obtained using an Intellivue MX450 patient monitor (Philips). Volunteers fasted for 8 to 10 hours prior to the recruitment appointment, and blood was drawn for the following tests: (1) lipid and glucose panel and (2) serum sphingolipid profiling. Additionally, the volunteers also underwent a Pagewriter TC30 16-lead ECG test (Philips). HRs were obtained from two separate sources, the blood pressure monitor ("ABPM_HR") and from the ECG reading ("ECG_HR").

**Clinical risk markers and thresholds**

The following clinical markers were considered in the study: BMI, WC, SBP, and DBP as well as fasting levels of TotalChol, HDL, LDL, TG, and FBG. Thresholds used to define risk levels (S3 Table) are as follows: High BMI (>27.5), High WC (>100 cm for males, >90 cm for
females), High SBP (>140 mmHg), High DBP (>90 mmHg), High TotalChol (>6.2 mmol/l), Low HDL (<1 mmol/l), High LDL (>4.1 mmol/l), High TG (>2.3 mmol/l), and High FBG (>6 mmol/l).

**Association tests**

Multiple linear regression and logistic regression analyses described in this study were conducted using the GLM (generalized linear model) function in R. For multiple linear regression, a Gaussian error distribution was used, whereas a binomial one was used for logistic regression. When gender was considered as a covariate, the female gender was set as the reference level.

For logistic regression analysis between wearable metrics and clinical parameters, two models were used depending on the metric. For step-based metrics, the model is Clinical_Marker ~ Age + Gender + Metric + Gender \times Metric, whereas for RHR-based metrics, the model is Clinical_Marker ~ Age + Gender + Metric. ORs and p-values reported for step-based metrics are for the Gender \times Metric interaction term. To ensure that results from various metrics are comparable, association analyses were conducted on a subset of subjects (223/233) with valid measurements for all metric types (i.e., DailySteps, RestingHR, ABPM_HR, ECG_HR, GPAAQ score). For logistic regression between activity clusters (AM cluster as reference level) and clinical markers, the following model was used: Clinical_Marker ~ Age + Gender + Daily-Steps + Gender \times DailySteps + ActivityCluster.

**CMR**

CMR of the volunteers was performed using either a Magnetom Aera 1.5T (Siemens) or Inge-nia 3T (Phillips) scanner under previously described settings [23]. Parameters such as cardiac volumes and mass were analyzed from imaging data using the CMR42 software (Circle Cardiovascular Imaging) and standardized protocols [23]. Four cardiac parameters were considered in this study: LVM, LVEDV, RVEDV, and AoF, with the first three being indexed to BSA according to the Dubois formula [47]. When performing multiple linear regression, adjustment was made for age, gender, and SBP. In the case of AoF, additional adjustment was made for weight and height. Only cardiac parameters with values within 2 SDs from their mean value were included for analysis. Numbers of data points analyzed for each cardiac parameter are as follows: LVM (n = 202), LVEDV (n = 216), RVEDV (n = 126), and AoF (n = 203). For logistic regression analysis of abnormally high BSA-indexed LVM against volunteer physical activity, only those of Chinese ethnicity were considered (n = 192). Cutoffs for defining abnormal BSA-indexed LVM were obtained from a study of 180 healthy Singaporeans (70 g/m² for males, 50 g/m² for females) [23].

**Lipidomics profiling and analysis**

Lipid internal standard mix (Ceramide/Sphingoid Internal Standard Mixture I, Avanti Polar Lipids) of 500 pmol was added to 100 μl of serum in a microcentrifuge tube. After an equilibration period of 30 s, 1.2 ml of HPLC-grade methanol was added to the mixture, followed by vortexing. The mixture was then incubated at 50°C for 10 min, followed by centrifugation to pellet the precipitated protein. The supernatant was then removed and placed in a clean microcentrifuge tube for drying under nitrogen gas. To reconstitute the dried extract, 100 μl of methanol was then used. The reconstituted lipid solution was then separated using a liquid chromatography–mass spectrometry (LC-MS) system (Agilent 1260) and a Thermo Scientific Accucore HILIC column (100 × 2.1 mm; particle size 2.6 μm). Mobile phase A consisted of acetonitrile/water (95:5) with 10 mM ammonium acetate, pH 8.0, and mobile phase B consisted of acetonitrile/water (50:50) with 10 mM ammonium acetate, pH 8.0. For the separation,
the column was equilibrated with 100% mobile phase A, increasing to 20% mobile phase B in 5 min, then held for 5 min. The column was then re-equilibrated with 100% mobile phase A for 5 min. Finally, mass spectrometry (MS) and data acquisition were performed using an Agilent 6430 triple-quadrupole mass spectrometer. As data were generated in two batches, normalization was performed within each batch on raw values (measured in pmols) by performing z-score transformation on a per-sphingolipid basis, prior to combining the data. Odd-chain sphingolipids and sphingolipids with missing values in more than 20% of samples were excluded from analysis.

Software and statistical tests
All statistical analyses in this study were performed using the R statistical environment. Unless otherwise stated, correlations described in this study are Spearman correlation coefficients. Adjustment for multiple testing in the lipidomics analysis was done using the Benjamini-Hochberg FDR method [48].

Supporting information

S1 Table. Results of logistic regression analysis of CVMD risk markers and various metrics, wearable and nonwearable. p-Values are shown, with ORs and 95% CIs shown in brackets. Highlighted cells have \( p < 0.05 \). p-Values for DailySteps and GPPAQ score are \( p \)-values for the Gender \( \times \) Metric interaction term. Cells with bold values indicate those for which RestingHR performs better compared with ECG_HR. CVMD, cardiovascular and metabolic disorder; DailySteps, average daily steps; ECG_HR, RHR measured by an electrocardiogram test; GPPAQ, General Practice Physical Activity Questionnaire; OR, odds ratio; RestingHR, wearable-derived RHR; RHR, resting heart rate.

S2 Table. Summary of multiple linear regression results for LVM, LVEDV, RVEDV, and AoF using both continuous (DailySteps) and categorical measures of physical activity, as well as RestingHR. Cat I–Cat IV denotes the categorical grouping of subjects based on DailySteps, with Cat I set as the reference. For comparison, results for questionnaire-based (GPPAQ) physical activity scores (as continuous predictors) are shown. Highlighted cells have \( p < 0.05 \). AoF, aortic forward flow; BSA, body surface area; DailySteps, average daily steps; GPPAQ, General Practice Physical Activity Questionnaire; LVEDV, left ventricular end-diastolic volume; LVM, left ventricular mass; RestingHR, wearable-derived RHR; RHR, resting heart rate; RVEDV, right ventricular end-diastolic volume.

S3 Table. Sources for thresholds used to define clinical risk markers.

S1 Data. Characteristics of study participants.

S2 Data. All data and R code used in this work.

Acknowledgments
We would like to thank the volunteers for their participation, as well as the NHCS and SingHEART Clinical Research Coordinators.
Author Contributions

Conceptualization: Weng Khong Lim, Sonia Davila, Stuart Alexander Cook, Khung Keong Yeo, Patrick Tan.

Data curation: Weng Khong Lim, Jing Xian Teo.

Formal analysis: Weng Khong Lim, Sonia Davila, Jing Xian Teo, Christopher Blöcker, Jing Quan Lim, Jianhong Ching, Jonathan Jiunn Liang Yap, Swee Yaw Tan, Anders Sahlén, Calvin Woon-Loong Chin, Bin Tean Teh, Steven G. Rozen.

Funding acquisition: Stuart Alexander Cook, Khung Keong Yeo, Patrick Tan.

Investigation: Weng Khong Lim, Jonathan Jiunn Liang Yap, Swee Yaw Tan, Anders Sahlén, Calvin Woon-Loong Chin, Bin Tean Teh.

Methodology: Weng Khong Lim, Sonia Davila, Chengxi Yang, Chee Jian Pua, Jianhong Ching, Calvin Woon-Loong Chin, Bin Tean Teh.

Project administration: Sonia Davila.

Resources: Weng Khong Lim, Chengxi Yang, Chee Jian Pua, Jianhong Ching.

Software: Weng Khong Lim, Jing Xian Teo, Christopher Blöcker, Jing Quan Lim.

Supervision: Weng Khong Lim, Stuart Alexander Cook, Khung Keong Yeo, Patrick Tan.

Visualization: Weng Khong Lim, Jing Quan Lim.

Writing – original draft: Weng Khong Lim, Sonia Davila, Stuart Alexander Cook, Khung Keong Yeo, Patrick Tan.

Writing – review & editing: Weng Khong Lim, Sonia Davila, Stuart Alexander Cook, Khung Keong Yeo, Patrick Tan.

References

1. Chuah SHW, Rauschnabel PA, Krey N, Nguyen B, Ramayah T, Lade S. Wearable technologies: The role of usefulness and visibility in smartwatch adoption. Comput Hum Behav. 2016; 65: 276–284. https://doi.org/10.1016/j.chb.2016.07.047

2. Li H, Wu J, Gao Y, Shi Y. Examining individuals’ adoption of healthcare wearable devices: An empirical study from privacy calculus perspective. Int J Med Inf. 2016; 88: 8–17. https://doi.org/10.1016/j.ijmedinf.2015.12.010 PMID: 26878757

3. Lamkin P. Wearable Tech Market To Be Worth $34 Billion By 2020. In: Forbes [Internet]. [cited 8 May 2017]. Available from: http://www.forbes.com/sites/paullamkin/2016/02/17/wearable-tech-market-to-be-worth-34-billion-by-2020/.

4. Fox K, Borjer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, et al. Resting Heart Rate in Cardiovascular Disease. J Am Coll Cardiol. 2007; 50: 823–830. https://doi.org/10.1016/j.jacc.2007.04.079 PMID: 17719466

5. Cooney MT, Vartiainen E, Laakikainen T, Laakikainen T, Juolevi A, Dudina A, et al. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J. 2010; 159: 612–619.e3. https://doi.org/10.1016/j.ahj.2009.12.029 PMID: 20362720

6. Cook S, Togni M, Schaub MC, Wenaweser P, Hess OM. High heart rate: a cardiovascular risk factor? Eur Heart J. 2006; 27: 2387–2393. https://doi.org/10.1093/eurheartj/ehl259 PMID: 17000632

7. Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic diseases. Compr Physiol. 2012; 2: 1143–1211. https://doi.org/10.1002/cphy.c110025 PMID: 23739288

8. Strath SJ, Rowley TW. Wearables for Promoting Physical Activity. Clin Chem. 2017; clinchem.2017.272369. https://doi.org/10.1373/clinchem.2017.272369 PMID: 29118062

9. Finkelstein EA, Haaland BA, Bilger M, Sahasranaman A, Sloan RA, Nang EK, et al. Effectiveness of activity trackers with and without incentives to increase physical activity (TRIPPA): a randomised
controlled trial. Lancet Diabetes Endocrinol. 2016; 4: 983–995. https://doi.org/10.1016/S2213-8587(16)30284-4 PMID: 27717766

10. Li X, Dunn J, Salins D, Zhou G, Zhou W, Rose SMS-F, et al. Digital Health: Tracking Physiomes and Activity Using Wearable Biosensors Reveals Useful Health-Related Information. PLoS Biol. 2017; 15(1): e2001402. https://doi.org/10.1371/journal.pbio.2001402 PMID: 28081144

11. Price ND, Magis AT, Earls JC, Glusman G, Levy R, Lausted C, et al. A wellness study of 108 individuals using personal, dense, dynamic data clouds. Nat Biotechnol. 2017; 35: 747. https://doi.org/10.1038/nbt.3870 PMID: 28714965

12. Ballinger B. Screening for Hypertension and Sleep Apnea with DeepHeart. In: Cardiogram [Internet]. 13 Nov 2017 [cited 20 Dec 2017]. Available from: https://blog.cardiogram.com/screening-for-hypertension-and-sleep-apnea-with-deepheart-416c9bc03efc.

13. Ballinger B. Atrial fibrillation and optical heart rate sensors. In: Cardiogram [Internet]. 12 Sep 2017 [cited 19 Dec 2017]. Available from: https://blog.cardiogram.com/atrial-fibrillation-and-optical-heart-rate-sensors-262d6bd50dcld.

14. Tison GH, Singh AC, Ohashi DA, Hsieh JT, Ballinger BM, Olgin JE, et al. Abstract 21042: Cardiovascular Risk Stratification Using Off-the-Shelf Wearables and a Multi-Task Deep Learning Algorithm. Circulation. 2017; 136: A21042–A21042.

15. Chu AHY, Ng SHX, Paknezhad M, Gauterin A, Koh D, Brown MS, et al. Comparison of wrist-worn Fitbit Flex and waist-worn ActiGraph for measuring steps in free-living adults. PLoS ONE. 2017; 12(2): e0172535. https://doi.org/10.1371/journal.pone.0172535 PMID: 28234953

16. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet Lond Engl. 1986; 1: 307–310.

17. Jensen MT, Suadicani P, Hein HO, Gyntelberg F. Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen Male Study. Heart. 2013; 99: 882–887. https://doi.org/10.1136/heartjnl-2012-303375 PMID: 23595657

18. Walch OJ, Cochran A, Forger DB. A global quantification of “normal” sleep schedules using smartphone data. Sci Adv. 2016; 2: e1501705. https://doi.org/10.1126/sciadv.1501705 PMID: 27386531

19. Duffy JF, Zitting K-M, Chinoy ED. Aging and Circadian Rhythms. Sleep Med Clin. 2015; 10: 423–434. https://doi.org/10.1016/j.smcl.2015.08.002 PMID: 26568120

20. Cortright RN, Chandler MP, Lemon PWR, DiCarlo SE. Daily Exercise Reduces Fat, Protein and Body Mass in Male but not Female Rats. Physiol Behav. 1997; 62: 105–111. https://doi.org/10.1016/S0031-9384(97)00148-0 PMID: 9226349

21. Geer EB, Shen W. Gender Differences in Insulin Resistance, Body Composition, and Energy Balance. Gend Med. 2009; 6: 60–75. https://doi.org/10.1016/j.gendmed.2009.02.002 PMID: 19381219

22. Dawes TJW, Corden B, Cotter S, de Marvao A, Walsh R, Ware JS, et al. Moderate Physical Activity in Healthy Adults is Associated With Cardiac Remodeling. Circ Cardiovasc Imaging. 2016; 9: e004712. https://doi.org/10.1161/CIRCIMAGING.116.004712 PMID: 27502059

23. Le T-T, Tan RS, Deyn MD, Goh EPC, Han Y, Leong BR, et al. Cardiovascular magnetic resonance reference ranges for the heart and aorta in Chinese at 3T. J Cardiovasc Magn Reson. 2016; 18: 21. https://doi.org/10.1186/s12968-016-0236-3 PMID: 27071974

24. Bergman BC, Brozinick JT, Strauss A, Bacon S, Kerege A, Bui HH, et al. Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans. Am J Physiol—Endocrinol Metab. 2015; 309: E398–E408. https://doi.org/10.1152/ajpendo.00134.2015 PMID: 26166844

25. Fabbri E, Yang A, Simonick EM, Chia CW, Zoli M, Haughey NJ, et al. Circulating ceramides are inversely associated with cardiorespiratory fitness in participants aged 54–96 years from the Baltimore Longitudinal Study of Aging. Aging Cell. 2016; 15(1): e2001402. https://doi.org/10.1371/journal.pbio.2001402 PMID: 28081144

26. Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, DeFronzo RA, et al. Plasma Ceramides Are Elevated in Obese Subjects With Type 2 Diabetes and Correlate With the Severity of Insulin Resistance. Diabetes. 2009; 58: 337–343. https://doi.org/10.2337/db08-1228 PMID: 19008343

27. Mamta M, Meikle PJ, Kulkarni H, Weir JM, Barbauer C, Jowett JB, et al. Plasma dihydroceramide species associate with waist circumference in Mexican American families. Obes Silver Spring Md. 2014; 22: 950–956. https://doi.org/10.1002/oby.20598 PMID: 23929697

28. Bergman BC, Brozinick JT, Strauss A, Bacon S, Kerege A, Bui HH, et al. Muscle sphingolipids during rest and exercise: a C18:0 signature for insulin resistance in humans. Diabetologia. 2016; 59: 785–798. https://doi.org/10.1007/s00125-015-3850-y PMID: 26739815

29. Maza MP de la, Rodriguez JM, Hirsch S, Leiva L, Barrera G, Bunout D. Skeletal muscle ceramide species in men with abdominal obesity. J Nutr Health Aging. 2015; 19: 389–396. https://doi.org/10.1007/s12603-014-0548-7 PMID: 25809802
30. Dubé JJ, Amati F, Toledo FGS, Stefanovic-Racic M, Rossi A, Coen P, et al. Effects of weight loss and exercise on insulin resistance, and intramyocellular triacylglycerol, diacylglycerol and ceramide. Diabetologia. 2011; 54: 1147–1156. https://doi.org/10.1007/s00125-011-2065-0 PMID: 21327867

31. Straczkowski M, Kowalska S, Nikolajuk A, Dzienis-Straczkowska S, Kinalska I, Baranowski M, et al. Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle. Diabetes. 2004; 53: 1215–1221. PMID: 15111499

32. Alhoff T, Sosić R, Hicks JL, King AC, Delp SL, Leskovec J. Large-scale physical activity data reveal worldwide activity inequality. Nature. 2017;advance online publication. https://doi.org/10.1038/nature23018 PMID: 28693034

33. Palatini P, Mos L, Santonastaso M, Zanatta N, Mormino P, Saladini F, et al. Resting heart rate as a predictor of body weight gain in the early stage of hypertension. Obes Silver Spring Md. 2011; 19: 618–623. https://doi.org/10.1038/obesity.2010.191 PMID: 20814417

34. Tan CE, Emmanuel SC, Tan BY, Jacob E. Prevalence of diabetes and ethnic differences in cardiovascular risk factors. The 1992 Singapore National Health Survey. Diabetes Care. 1999; 22: 241–247. https://doi.org/10.2337/diacare.22.2.241 PMID: 10333940

35. Baggish AL, Wood MJ. Athlete’s Heart and Cardiovascular Care of the Athlete: Scientific and Clinical Update. Circulation. 2011; 123: 2723–2735. https://doi.org/10.1161/CIRCULATIONAHA.110.981571 PMID: 21670241

36. La Gerche A, Burns AT, Mooney DJ, Inder WJ, Taylor AJ, Bogaert J, et al. Exercise-induced right ventricular dysfunction and structural remodelling in endurance athletes. Eur Heart J. 2012; 33: 998–1006. https://doi.org/10.1093/eurheartj/ehr397 PMID: 22160404

37. Bohm P, Schneider G, Linneweber L, Rentzsch A, Krämer N, Abdul-Khalil H, et al. Right and Left Ventricular Function and Mass in Male Elite Master Athletes: A Controlled Contrast-Enhanced Cardiovascular Magnetic Resonance Study. Circulation. 2016; 133: 1927–1935. https://doi.org/10.1161/CIRCULATIONAHA.115.020975 PMID: 27073129

38. Maron BJ. Distinguishing hypertrophic cardiomyopathy from athlete’s heart: a clinical problem of increasing magnitude and significance. Heart. 2005; 91: 1380–1382. https://doi.org/10.1136/hrt.2005.060962 PMID: 16230430

39. Petersen SE, Matthews PM, Bamberg F, Bluemke DA, Francis JM, Friedrich MG, et al. Imaging in population science: cardiovascular magnetic resonance in 100,000 participants of UbBiobank—rationale, challenges and approaches. J Cardiovasc Magn Reson. 2013; 15: 46. https://doi.org/10.1186/1532-429X-15-46 PMID: 23714095

40. Bamberg F, Kauczor H-U, Weckbach S, Schlett CL, Forsting M, Ladd SC, et al. Whole-Body MR Imaging in the German National Cohort: Rationale, Design, and Technical Background. Radiology. 2015; 277: 206–220. https://doi.org/10.1148/radiol.2015142272 PMID: 25989618

41. Medrano-Gracia P, Cowan BR, Suinesiaputra A, Young AA. Challenges of Cardiac Image Analysis in Large-Scale Population-Based Studies. Curr Cardiol Rep. 2015; 17: 563. https://doi.org/10.1007/s11886-015-0563-2 PMID: 25648627

42. Chavez JA, Summers SA. A ceramide-centric view of insulin resistance. Cell Metab. 2012; 15: 585–594. https://doi.org/10.1016/j.cmet.2012.04.002 PMID: 22560211

43. Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016; 37: 1967–1976. https://doi.org/10.1093/eurheartj/ehw148 PMID: 27125947

44. Tarasov K, Ekroos K, Sysi-Aho M, Kauhanen D, et al. Plasma ceramides predict cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J Clin Endocrinol Metab. 2014; 99: E45–E52. https://doi.org/10.1210/jc.2013-2559 PMID: 24243630

45. Summers SA. Could Ceramides Become the New Cholesterol? Cell Metab. 2018; https://doi.org/10.1016/j.cmet.2017.12.003 PMID: 29307517

46. Kasumov T, Solomon TPJ, Hwang C, Huang H, Haus JM, Zhang R, et al. Improved Insulin Sensitivity After Exercise Training is Linked to Reduced Plasma C14:0 Ceramide in Obesity and Type 2 Diabetes. Obes Silver Spring Md. 2015; 23: 1414–1421. https://doi.org/10.1002/oby.21117 PMID: 25966363

47. Dubois D, Dubois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916; 17: 863–871.

48. Benjamin Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B Methodol. 1995; 57: 289–300. https://doi.org/10.2307/2346101